TAG Statement to Human Rights Council on Human Rights Concerns in the UAE
TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE).
Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics
In July 2017, 37 treatment activists from 17 countries—including 14 low- and middle-income countries (LMICs)—met with representatives from three generics and three diagnostics companies. This Hepatitis C World Community Advisory Board meeting was an opportunity for activists to present demands…
US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation
TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
TAG Letter to House E&C Committee Opposing “Right to Try” Bills
TAG’s comments to the Health Subcommittee of the U.S. House of Representatives Energy and Commerce Committee, in association with its hearing, “Examining Patient Access to Investigational Drugs,” and the deliberations of H.R. 1020, the Compassionate Freedom of Choice Act of 2017, and S. 204, the Right to Try Act of 2017.
Hepatitis C Treatment Access in Prisons: Legal and Policy Challenges
On Monday, October 2, 2017, Treatment Access Group joined National Viral Hepatitis Roundtable and the Hepatitis Education Project to present this update on HCV DAA treatment access in the U.S. prison system. The webinar included information about newly available treatments,…
TAG Applauds Malaysian Government’s Decision to Make Generic form of Life-Saving Hep C Cure
The Government of Malaysia reaffirmed its commitment to affordable access to hepatitis C treatment by issuing a compulsory license on sofosbuvir (Sovaldi).
TAG’s Annual Pipeline Report: Promising New HIV, TB & HCV Drugs and Diagnostics
Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
HCV Pipeline: DAAs and Diagnostics in the Pangenotypic Era
July 2017 By Annette Gaudino INTRODUCTION The continued development of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has brought both multigenotypic and pangenotypic regimens to market, with more on the horizon. These simpler-to- prescribe regimens potentially eliminate the need…
TAG Earns Coveted 4-Star Rating from Charity Navigator
TAG’s strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.
House to People Living with HIV, HCV and TB: “Drop Dead”
Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.